IR Licensing and Partnerships

June 12th 2025

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine for potential distribution in low- and middle-income countries.

February 13th 2025

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis.

February 12th 2025

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

January 30th 2025

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung cancer who are PD-1 checkpoint inhibitor resistant.